Neuroimaging in moderate MDMA use: A systematic review
Neuroscience & Biobehavioral Reviews – December 30, 2015
Source: OpenAlex
Summary
Moderate MDMA use does not appear to lead to significant structural or functional brain changes, based on a review of 19 studies involving neuroimaging techniques. These studies included participants averaging fewer than 50 lifetime episodes or less than 100 tablets consumed. Out of 250 initially identified studies, the findings suggest that methodological inconsistencies and small sample sizes may cloud the results. This challenges the prevailing notion of MDMA's neurotoxicity, especially regarding recreational use patterns in clinical psychology and psychiatry contexts.
Abstract
MDMA ("ecstasy") is widely used as a recreational drug, although there has been some debate about its neurotoxic effects in humans. However, most studies have investigated subjects with heavy use patterns, and the effects of transient MDMA use are unclear. In this review, we therefore focus on subjects with moderate use patterns, in order to assess the evidence for harmful effects. We searched for studies applying neuroimaging techniques in man. Studies were included if they provided at least one group with an average of <50 lifetime episodes of ecstasy use or an average lifetime consumption of <100 ecstasy tablets. All studies published before July 2015 were included. Of the 250 studies identified in the database search, 19 were included. There is no convincing evidence that moderate MDMA use is associated with structural or functional brain alterations in neuroimaging measures. The lack of significant results was associated with high methodological heterogeneity in terms of dosages and co-consumption of other drugs, low quality of studies and small sample sizes.